Rollout of COVID antibody therapy requires clinician feedback, U.S. officials say
By
Alicia Lasek
Nov 11, 2020
Federal agencies say they will depend on clinician input during distribution of Eli Lilly’s new intravenous antibody therapy for high-risk COVID-19 patients.